Clinical Trials · NCT01007851

Single Dose Gonadotropin-releasing Hormone (GnRH) Agonist Administration in the Luteal Phase of GnRH Antagonist Stimulated ICSI-ET Cycles

TerminatedPhase 3Gonadorelin (Prohibited)
Phase
Phase 3
Recruitment status
Terminated
Sponsor
V.K.V. American Hospital, Istanbul
Enrollment
0
Start date
Sep 2006
Locations
1 site, Turkey (Türkiye)
Primary endpoint
Ongoing pregnancy beyond 20th gestational week
View Gonadorelin compound reference